BridgeBio Pharma Inc
BBIOHealthcare|Biotechnology|USA
$85.81
-4.28 (-4.75%)
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07062848 An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems. | Transthyretin (TTR) Amyloid Cardiomyopathy | Active | 1,500,000 | — | — | |
| NCT05480865 SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | Solid Tumor, Adult, Metastatic Solid Tumor | P1 | Terminated | 28 | RCT, Open-label | BBP-398, sotorasib |
| NCT04528836 First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | Tumor, Solid | P1 | Terminated | 72 | Open-label | BBP-398 (Formerly known as IACS-15509) |
| NCT05375084 SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | Non Small Cell Lung Cancer, Solid Tumor | P1 | Terminated | 21 | Open-label | BBP-398 with nivolumab |
| NCT07398950 Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | ATTR Amyloidosis With Cardiomyopathy, Heart Failure | Not Yet Recruiting | 150 | — | — |